A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma

Recruiting now · Phase 1/Phase 2

Conditions studied: Glioblastoma

In brief

This study is an open-label, single-arm Phase I/II clinical trial with the primary objective of evaluating the safety, tolerability, and efficacy of VRT106 in patients with recurrent/progressive glioblastoma.

Key facts

Study ID

NCT07093814

Run by

Guangzhou Virotech Pharmaceutical Co., Ltd.

People needed

42

Starts

2025-09-02

Expected to finish

2029-06-30

Last updated by the study team

2026-01-02

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects voluntarily participate in the clinical study; fully understand and be informed about the study and sign the ICF; and are willing to follow and have the ability to complete all trial procedures.
• Males and females are aged at 18-70 years (including borderline values) at the time of signing the ICF, male or female.
• Diagnosed with recurrent/progressive glioblastoma.
• Karnofsky Performance Status (KPS) score ≥60 within 28 days prior to the first administration of the study drug.
• An expected survival time of≥3 months.
• Have sufficient organ function.
• Female patients of childbearing potential must have a negative serum pregnancy test result within 7 days prior to the first use of the study drug (if a false-positive pregnancy test result is due to non-pregnancy factors such as illness, further testing via ultrasound or other methods is required, and the investigator must confirm the absence of pregnancy before enrollment).
• Subjects of childbearing potential (males and females) agree to use effective birth control with their partner from signing informed consent to at least 90 days after the last dose.

You may not qualify if…

• Patients with extracranial metastases.
• Previously received treatment with oncolytic viruses, gene therapy.
• Subject has received treatment with other unlisted clinical investigational drugs/devices within 4 weeks prior to the first dose of VRT106.
• Subject is known to have an allergic reaction to any of the components of VRT106.
• Patients who can't have a cranial MRI scan.
• Women who are breastfeeding.

Where it is running

• The Second Affiliated Hospital of Zhejiang University School of Medicine — Hangzhou, Zhejiang, China (enrolling)
• Sun Yat-sen University Cancer Center — Guangzhou, Guangdong, China (enrolling)
• Shenzhen Second People's Hospital — Shenzhen, Guangdong, China (enrolling)
• The Fifth Affiliated Hospital of Sun Yat-sen University — Zhuhai, Guangdong, China (enrolling)
• Guangxi Medical University Cancer Hospital — Nanning, Guangxi, China (enrolling)
• Qilu Hospital of Shandong University — Jinan, Shandong, China
• Tangdu Hospital of Air Force Medical University of the PLA — Xi’an, Shanxi, China
• Sanbo Brain Hospital Capital Medical University — Beijing, Beijing Municipality, China
• The Cancer Hospital Affiliated to Chongqing University — Chongqing, Chongqing Municipality, China
• Nanfang Hospital, Southern Medical University — Guangzhou, Guangdong, China
• The First Affiliated Hospital of USTC — Hefei, Anhui, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.